{"id":414676,"date":"2021-01-14T07:03:29","date_gmt":"2021-01-14T12:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414676"},"modified":"2021-01-14T07:03:29","modified_gmt":"2021-01-14T12:03:29","slug":"microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/","title":{"rendered":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Management Presenting at Needham Growth Conference Today at 2:00pm ET<\/em>\n      <\/p>\n<p align=\"justify\">HINGHAM, Mass., Jan.  14, 2021  (GLOBE NEWSWIRE) &#8212; The continued progression of Microbot Medical Inc.\u2019s (Nasdaq: MBOT) LIBERTY\u2122\u00a0Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world\u2019s first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company\u2019s assertion that LIBERTY will potentially allow physicians to safely and easily conduct catheter-based peripheral and neurovascular procedures remotely, avoiding radiation exposure, physical strain and the risk of cross contamination.<\/p>\n<p align=\"justify\">\u201cAs we continue to evaluate LIBERTY in the hands of leading clinicians, the system is performing to our expectations and achieving the desired clinical and usability outcomes,\u201d commented Harel Gadot, Chief Executive Officer, President, and Chairman. \u201cAdditional studies are planned throughout the coming year to allow us to achieve our regulatory goals.\u201d<\/p>\n<p align=\"justify\">The procedure was performed by Dr. Gal Yaniv, a recently added member of the Company\u2019s Scientific Advisory Board (SAB), who also serves as Director of Endovascular Neurosurgery at Sheba Tel HaShomer City of Health and Chief Medical Officer of Aidoc Medical, a full body imaging AI software firm. Dr. Yaniv conducted the procedure and the results demonstrated robust navigation capabilities and intuitive usability.<\/p>\n<p align=\"justify\">Mr. Gadot will be presenting an overview of the Company later today at 2:00pm ET. The live and archived replays of the presentation may be accessed via the \u2018Investors\u2019 section, under \u2018Presentation + Resources\u2019 of the Company\u2019s website at www.microbotmedical.com.<\/p>\n<p align=\"start\">\n        <strong>About Microbot Medical<\/strong>\n      <\/p>\n<p align=\"justify\">Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot\u2019s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).<\/p>\n<p align=\"justify\">Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http:\/\/www.microbotmedical.com.<\/p>\n<p align=\"start\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and\/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects\u201d and \u201cestimates\u201d) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and\/or commercialization of potential products, including LIBERTY\u2122\u00a0and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading \u201cRisk Factors\u201d in Microbot Medical\u2019s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC\u2019s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p align=\"start\">\n        <strong>Investor Contact: <\/strong>\n      <\/p>\n<p align=\"start\">Michael Polyviou <br \/> EVC Group <br \/> mpolyviou@evcgroup.com <br \/> 732-933-2754<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dd0c602c-a099-4219-9a01-e34223710d12\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; The continued progression of Microbot Medical Inc.\u2019s (Nasdaq: MBOT) LIBERTY\u2122\u00a0Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world\u2019s first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company\u2019s assertion that LIBERTY will potentially allow &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414676","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; The continued progression of Microbot Medical Inc.\u2019s (Nasdaq: MBOT) LIBERTY\u2122\u00a0Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world\u2019s first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company\u2019s assertion that LIBERTY will potentially allow &hellip; Continue reading &quot;Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T12:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System\",\"datePublished\":\"2021-01-14T12:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/\"},\"wordCount\":676,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/\",\"name\":\"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\",\"datePublished\":\"2021-01-14T12:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/","og_locale":"en_US","og_type":"article","og_title":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk","og_description":"Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; The continued progression of Microbot Medical Inc.\u2019s (Nasdaq: MBOT) LIBERTY\u2122\u00a0Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world\u2019s first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company\u2019s assertion that LIBERTY will potentially allow &hellip; Continue reading \"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T12:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System","datePublished":"2021-01-14T12:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/"},"wordCount":676,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/","name":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=","datePublished":"2021-01-14T12:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTU3NCMzOTE4Mjc5IzIwODIxMTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-libertytm-robotic-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414676"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414676\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}